EDGAR·FLOW

Caribou Biosciences, Inc. — Form 8-K

Filed October 6, 2026 · analyzed by the 8-K Agent
8-K ▼ Likely negative significance 92/100
What the filing says
Caribou Biosciences announced it is evaluating strategic alternatives (merger, acquisition, or asset sale) and discontinuing development of vispa-cel and CB-011 allogeneic CAR-T therapies due to financing challenges in the CAR-T market. The company will implement substantial workforce reductions expected to complete in Q4 2026. As of June 30, 2026, Caribou held $113.8 million in cash, cash equivalents, and marketable securities—essentially equal to the company's ~$112.5M public market value.
Why this rating

Company abandoning all lead pipeline programs and pursuing sale/merger; cash position (~100% of market cap) means near-total dilution likely; existential pivot for clinical-stage biotech.

Tradability signal
SHORT conviction 67/100 · expected -2.99% over 4 hrs

SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (63 in this cell) moved +4.18% in the called direction over 4 hrs; shrunk for sample size that's a +2.99% edge. Price is down 47.5% since the filing hit EDGAR — the slide has begun. Caution: sub-$5 shorts can be hard to borrow — treat as avoid-longs if no locate. Exit plan: HARD stop 8% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it negative)
before filing · preread
$1.14 ▲ 80.73%
at our read · unknown
$0.63
+10 min · unknown
$0.59 ▼ 5.73%
+30 min · unknown
$0.58 ▼ 7.48%
+1 hr · unknown
$0.64 ▲ 1.11%
+4 hrs · unknown
$0.61 ▼ 2.39%

The stock had already moved -44.67% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ CRBU · stock on Yahoo Finance ↗

See more from October 6, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.